Oracle Corporation (NYSE:ORCL) announced on Thursday that it is working with the National Institutes of Health (NIH) to support COVID-19 vaccine trials.
The National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, recently established the COVID-19 Prevention Network (CoVPN). Its goal is to register millions of volunteers for large-scale clinical testing of vaccines and monoclonal antibodies intended to protect people from COVID-19.
As part of this initiative, Oracle has developed a cloud system called the CoVPN Volunteer Screening Registry to identify and screen volunteers who want to participate in COVID-19 clinical trials. More than 100,000 people have registered since the system went live a week ago.
The program is expected to support hundreds of clinical trial sites across the United States and internationally by the end of the year, Oracle said.
NICE recommends ALK's ACARIZAX for house dust mite allergic rhinitis treatment in UK's NHS
European Commission approves Palforzia for toddlers with peanut allergy
Eli Lilly and Co receives approval from FDA for Zepbound
CSL gains EMA backing for Garadacimab as HAE prophylactic treatment
Allergy Therapeutics reports positive data from VLP Peanut PROTECT trial
CBC Group acquires UCB's mature neurology and allergy business in China
Allergy Therapeutics begins Phase III trial for grass allergy treatment in children